{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:49:41Z","timestamp":1791805781551,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ymthe.2026.09.031","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:36:30Z","timestamp":1790404590000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel HIV fusion-inhibitory lipopeptides exhibit dramatically improved activity against resistant mutants"],"prefix":"10.1016","author":[{"given":"Yuanmei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhu","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3229-249X","authenticated-orcid":false,"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-3582","authenticated-orcid":false,"given":"Sheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-6696","authenticated-orcid":false,"given":"Yuxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.09.031_bib1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.biochem.70.1.777","article-title":"Mechanisms of viral membrane fusion and its inhibition","volume":"70","author":"Eckert","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ymthe.2026.09.031_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","article-title":"HIV entry and its inhibition","volume":"93","author":"Chan","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.031_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.09.031_bib4","doi-asserted-by":"crossref","first-page":"12303","DOI":"10.1073\/pnas.94.23.12303","article-title":"Atomic structure of a thermostable subdomain of HIV-1 gp41","volume":"94","author":"Tan","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.031_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.031_bib6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.2174\/1381612811319100004","article-title":"Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion","volume":"19","author":"He","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2026.09.031_bib7","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.2174\/138161210794079218","article-title":"Inhibition of HIV-1 by fusion inhibitors","volume":"16","author":"Eggink","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2026.09.031_bib8","doi-asserted-by":"crossref","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","article-title":"Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.031_bib9","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3390\/ijms25073659","article-title":"A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication","volume":"25","author":"Sever","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.09.031_bib10","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.031_bib11","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.09.031_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110362","article-title":"30 years of HIV therapy: Current and future antiviral drug targets","volume":"603","author":"Nuwagaba","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2026.09.031_bib13","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.bbamem.2011.06.020","article-title":"Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor","volume":"1808","author":"Ashkenazi","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2026.09.031_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/138161210790963751","article-title":"Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins","volume":"16","author":"Steffen","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2026.09.031_bib15","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1074\/jbc.M807169200","article-title":"Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20","volume":"284","author":"Izumi","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.031_bib16","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/JVI.02413-06","article-title":"Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors","volume":"81","author":"Ray","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib17","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","article-title":"Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target","volume":"95","author":"Chan","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.031_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0092-8674(00)80066-5","article-title":"Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket","volume":"99","author":"Eckert","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.031_bib19","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.031_bib20","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1073\/pnas.0901007106","article-title":"Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency","volume":"106","author":"Ingallinella","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.031_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.biocel.2008.08.039","article-title":"Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide","volume":"41","author":"Nishikawa","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib22","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.09.031_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032599","article-title":"Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor","volume":"7","author":"Chong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.09.031_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jinf.2022.05.034","article-title":"Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study","volume":"85","author":"Su","year":"2022","journal-title":"J. Infect."},{"key":"10.1016\/j.ymthe.2026.09.031_bib25","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study","volume":"133","author":"Su","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ymthe.2026.09.031_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cell.2021.11.032","article-title":"Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide","volume":"185","author":"Xue","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.09.031_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116228","article-title":"An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques","volume":"44","author":"Xue","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.09.031_bib28","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.3390\/ijms23126638","article-title":"In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor","volume":"23","author":"Hu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.09.031_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00384-20","article-title":"Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques","volume":"94","author":"Yu","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02044-17","article-title":"Mechanism of HIV-1 Resistance to an Electronically Constrained alpha-Helical Peptide Membrane Fusion Inhibitor","volume":"92","author":"Wu","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib31","doi-asserted-by":"crossref","first-page":"12467","DOI":"10.1128\/JVI.01741-15","article-title":"Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Su","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib32","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1128\/JVI.00373-15","article-title":"Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Su","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106190","article-title":"Structural characterization of HIV fusion inhibitor LP-98: Insights into antiviral and resistance mechanisms","volume":"239","author":"Liu","year":"2025","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2026.09.031_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00714-25","article-title":"Applications and limitations of the passenger hypothesis for HIV reservoir persistence and cure","volume":"99","author":"Schiffer","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib35","article-title":"Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control","volume":"2025","author":"Okesanya","year":"2025","journal-title":"AIDS Res. Treat."},{"key":"10.1016\/j.ymthe.2026.09.031_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11904-025-00723-6","article-title":"Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places","volume":"22","author":"Chen","year":"2025","journal-title":"Curr. Hiv\/aids Rep."},{"key":"10.1016\/j.ymthe.2026.09.031_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/COH.0000000000000849","article-title":"Persistent HIV-1 transcription during ART: time to reassess its significance?","volume":"19","author":"Fombellida-Lopez","year":"2024","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.ymthe.2026.09.031_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/v16071163","article-title":"HIV Persistence, Latency, and Cure Approaches: Where Are We Now?","volume":"16","author":"Chou","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2026.09.031_bib39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000001073","article-title":"Development of potent and long-acting HIV-1 fusion inhibitors","volume":"30","author":"Chong","year":"2016","journal-title":"Aids"},{"key":"10.1016\/j.ymthe.2026.09.031_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00288-17","article-title":"A Lipopeptide HIV-1\/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity","volume":"91","author":"Chong","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.micinf.2024.105366","article-title":"Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure","volume":"26","author":"Geng","year":"2024","journal-title":"Microbes Infect."},{"key":"10.1016\/j.ymthe.2026.09.031_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.106042","article-title":"Development of lipopeptide-based HIV-1\/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy","volume":"232","author":"Geng","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ymthe.2026.09.031_bib43","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","article-title":"Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus","volume":"293","author":"Zhu","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2026.09.031_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00831-17","article-title":"Enfuvirtide (T20)-based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implication for Viral Entry and Inhibition","volume":"91","author":"Ding","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00775-18","article-title":"Design of Novel HIV-1\/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models","volume":"92","author":"Chong","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib46","doi-asserted-by":"crossref","first-page":"e01088","DOI":"10.1128\/JVI.01088-18","article-title":"Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against HIV-1, HIV-2, and Simian Immunodeficiency Virus","volume":"92","author":"Chong","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007552","article-title":"Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques","volume":"15","author":"Chong","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2026.09.031_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02312-18","article-title":"Design and Characterization of Cholesterylated Peptide HIV-1\/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity","volume":"93","author":"Zhu","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01839-16","article-title":"A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus","volume":"91","author":"Xiong","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.09.031_bib50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0377-0427(99)00276-9","article-title":"A class of gradient unconstrained minimization algorithms with adaptive stepsize","volume":"114","author":"Vrahatis","year":"2000","journal-title":"J. Comput. Appl. Math."},{"key":"10.1016\/j.ymthe.2026.09.031_bib51","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: A linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ymthe.2026.09.031_bib52","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle Mesh Ewald - an N.Log(N) Method for Ewald Sums in Large Systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymthe.2026.09.031_bib53","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ymthe.2026.09.031_bib54","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.py: An Efficient Program for End-State Free Energy Calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ymthe.2026.09.031_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.biophys.36.040306.132550","article-title":"Calculation of protein-ligand binding affinities","volume":"36","author":"Gilson","year":"2007","journal-title":"Annu. Rev. Bioph Biom"},{"key":"10.1016\/j.ymthe.2026.09.031_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Dis."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:36:46Z","timestamp":1791805006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S1525001626008014"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.031","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel HIV fusion-inhibitory lipopeptides exhibit dramatically improved activity against resistant mutants","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}